Keresés eredménye

Típusa:
összetett keresés
Keresési paraméterek:
Susan Wroblewski, PhD | szakcikk |

<< < 1 > >>
1 találat 1 oldalon - ebből zárolt tartalom 1 db

A zárolt tartalmakat csak bejelentkezett felhasználók tekinthetik meg!

859 Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Overall Survival in Alcyone

Szerző: Maria-Victoria Mateos1 Michele Cavo2 Joan Bladé, MD, PhD3 Meletios A. Dimopoulos, MD4 Kenshi Suzuki, MD, PhD5 Andrzej Jakubowiak, MD, PhD6 Stefan Knop7 Chantal Doyen, MD8 Paulo Lucio, MD, PhD9 Zsolt Nagy, MD, PhD10 Ludek Pour, MD11 Mark Cook, MBChB, PhD12 Sebastian Grosicki, MD, PhD13 Andre H Crepaldi, MD14 Anna Marina Liberati15 Philip Campbell, MBBS, FRACP, FRCPA16 Tatiana Shelekhova17 Sung-Soo Yoon, MD, PhD18 Genadi Iosava, MD19 Tomoaki Fujisaki, MD, PhD20 Mamta Garg, MD, FRCP, FRCPath21 Maria Krevvata, PhD22 Jianping Wang23 Anupa Kudva, MD24 Jon Ukropec, PhD25 Susan Wroblewski, PhD26 Rachel Kobos, MD27 Jesus San-Miguel, MD, PhD28
1University Hospital of Salamanca/IBSAL, Salamanca, Spain
2Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy
3Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
4National and Kapodistrian University of Athens, Athens, Greece
5Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan
6University of Chicago Medical Center, Chicago, IL
7Würzburg University Medical Center, Würzburg, Germany
8Université catholique de Louvain, CHU UCL Namur, Yvoir, Belgium
9Champalimaud Centre for the Unknown, Lisbon, Portugal
10Semmelweis Egyetem, Budapest, Hungary
11University Hospital Brno, Brno, Czech Republic
12University Hospitals Birmingham NHS Trust, Birmingham, United Kingdom
13Department of Cancer Prevention, School of Public Health, Silesian Medical University, Katowice, Poland
14Clinica de Tratamento E, Cuiaba, Brazil
15Azienda Ospedaliera "Santa Maria", Terni, Italy
16Andrew Love Cancer Centre, Geelong, Australia
17Clinic of Professional Pathology, Saratov, RUS
18Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South)
19LTD “Medinvent” Institute of Health, Tbilisi, Georgia
20Matsuyama Red Cross Hospital, Matsuyama, Japan
21Leicester Royal Infirmary, Leicester, United Kingdom
22Janssen Research & Development, LLC, Spring House, PA
23Janssen Research & Development, LLC, Raritan, NJ
24Janssen Research & Development, LLC, Raritan, NJ
25Janssen Global Medical Affairs, Horsham, PA
26Janssen Research & Development, LLC, Spring House, PA
27Janssen Research & Development, LLC, Raritan, NJ
28Clínica Universidad de Navarra-CIMA, IDISNA, CIBERONC, Pamplona, Spain

Conclusions: For the first time, we demonstrate that the addition of DARA to VMP prolongs OS in patients with transplant-ineligible NDMM, with a 40% reduction in the risk of death versus VMP alone after a median follow-up of 40 months. D-VMP continued to demonstrate a significant PFS benefit, which was also maintained during the subsequent line of therapy. These findings, together with the phase 3 MAIA study (DARA plus lenalidomide/dexamethasone ...


<< < 1 > >>
1 találat 1 oldalon - ebből zárolt tartalom 1 db

A zárolt tartalmakat csak bejelentkezett felhasználók tekinthetik meg!